Specifically, autocrine TNF-α production is able to sustain CML stem cells and progenitor cells survival and pharmacological targeting of the TNF-α/NF-κB pathway is able to synergize with Bcr-Abl inhibition to a relevant degree. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.